



Proveca Ltd
WeWork
One St Peter's Square
Manchester
M2 3DE
UK

Tel: +44 (0) 161 468 2627
Email: info@proveca.com

Proveca Ltd. Transfer of Value Disclosure 2024

Methodological Note

Date of Preparation: March 2025

Introduction

Proveca Ltd. engages UK healthcare professionals (HCPs), other relevant decision makers (ORDMs), healthcare organisations (HCOs) and patient organisations to obtain independent and expert advice to ensure high standards of patient care. Such engagements include, but are not limited to research and development, educational and training events, advisory board meetings and attendance at conferences including promotional activities.

Proveca Ltd. has agreed to comply with the ABPI Code of Practice to document and publically disclose payments or other Transfers of Value (ToV) made directly or indirectly to HCPs, ORDMs, and HCOs. This note describes Proveca Ltd.'s method of disclosure of ToV for 2024, in accordance with the requirements of the ABPI Code of Practice.

In 2024, we reviewed all payments made by Proveca to external sources. The relevant payments for disclosure, as per the ABPI 2024 Code of Practice, were identified. These payments and their associated invoices were reviewed and added to the Disclosure UK 2024 template. The data was checked for validation prior to submission.

With regards to contracts, the ToV in this disclosure relates to contracts for one-off services. There were no long-standing agreements with HCPs.

Currency Aspects and Value Added Tax (VAT)

All disclosures of ToV made to UK HCPs, HCOs, and/or ORDMs in 2024 are declared in Pound Sterling (£). Where the original payment was made in another currency (for example, Euro (€)), the sum was converted to Pound Sterling (£) at the exchange rate prevailing at the time of the original payment.

Payments made to HCOs, including research and development payments, are declared in Pound Sterling (£) and values disclosed do not include VAT.

Medicines for Children

Registered in England and Wales. Company Number 7316783
Registered Company: Proveca Limited

Payments made to HCPs are declared in Pound Sterling (£) and the values disclosed are the full payment for fees and expenses with no tax added.

Lawful Basis for Disclosure

In 2022, Proveca Ltd. took the decision to move from 'Consent' to 'Legitimate Interests' as their lawful basis for Disclosure of ToVs. HCPs are not asked for formal consent to have their data published publicly and are informed by Proveca Ltd. that their data will be individually disclosed. Individuals have the right to raise objections to public publication of their ToV; no objections were received by Proveca Ltd. in 2024.

Definitions and Categories of Disclosure

HCP

Any member of the medical, dental, pharmacy or nursing profession and any other person who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine in relation to the annual disclosure of ToVs.

ORDM

In particular includes someone with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who is not a HCP.

HCO

Is defined as either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more health professionals or other relevant decision makers provide services.

Donations and Grants to HCOs

Donations and grants are funds, benefits-in-kind or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods and services to the benefit of the pharmaceutical company in return. Donations and grants to individuals are prohibited.

Contribution to Costs of Events

Sponsorship means a contribution, financial or otherwise, in whole or in part provided by or behalf of a company, towards an activity (including an event/meeting or material) performed, organised, created etc. by a HCO, patient organisation or other independent organisation.

Medicines for Children

Registered in England and Wales. Company Number 7316783
Registered Company: Proveca Limited

Support is the provision of a financial contribution, in whole or in part, whether paid directly or indirectly to individual HCPs or ORDMs to attend events/meetings, and is limited to travel, subsistence, accommodation and genuine registration fees extended in connection with events/meetings.

Contracted Services

Contracted services provided by HCPs, ORDMs, and HCOs include services such as speaking at and chairing meetings, involvement in medical/scientific studies, clinical trials or training services, writing articles and/or publications, participation at advisory board meetings, and participation in market research where such participation may involve remuneration and/or hospitality. Fees for services reflect fair market research for the services provided. Expenses are limited to travel, subsistence, and accommodation associated with the provision of the contracted service.

Non-Monetary ToV

Disclosure of non-monetary ToV is made at the equivalent value in monetary terms. No non-monetary ToV to patient organisations took place for the reporting period.

Collaborative Working ToV (Including Joint Working)

There were no Collaborative Working agreements in 2024.

Research and Development ToV

Research and Development ToV refers to any ToVs to HCPs or HCOs related to the planning or conduct of non-clinical studies, clinical trials and non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual or groups of HCPs specifically for the study. Research and Development related ToVs to HCOs and HCPs were disclosed in aggregate fashion as required by the ABPI Code of Practice.

Excluded ToVs

No ToVs were excluded for the 2024 reporting period.